8PXM

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH (1R,1'R)-7,7'-(pentane-1,5-diylbis(oxy))bis(1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one)

8PXM の概要

• エントリーDOI: 10.2210/pdb8pxm/pdb
• 分子名称: Bromodomain-containing protein 4, (1R)-7-[5-[[(1R)-1,3-dimethyl-2-oxidanylidene-1H-3-benzazepin-7-yl]oxy]pentoxy]-1,3-dimethyl-1H-3-benzazepin-2-one, 1,2-ETHANEDIOL, ... (4 entities in total)
• 機能のキーワード: inhibitor, histone, epigenetic reader, bromodomain, brd4, bromodomain containing protein 4, antagonist, transcription
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 30735.42

構造登録者

Chung, C.W. (登録日: 2023-07-23, 公開日: 2023-10-04)

主引用文献

Bamborough, P.,Chung, C.W.,Goodwin, N.C.,Mitchell, D.J.,Neipp, C.E.,Phillipou, A.,Preston, A.,Prinjha, R.K.,Soden, P.E.,Watson, R.J.,Demont, E.H.
Design and Characterization of 1,3-Dihydro-2 H -benzo[ d ]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors.
Acs Med.Chem.Lett., 14:1231-1236, 2023

PubMed Abstract: The 1,3-dihydro-2-benzo[]azepin-2-ones are potent and ligand-efficient pan-BET bromodomain inhibitors. Here we describe the extension of this template to exploit a bivalent mode of action, binding simultaneously to both bromodomains. Initially the linker length and attachment vectors compatible with bivalent binding were explored, leading to the discovery of exceptionally potent bivalent BET inhibitors within druglike rule-of-5 space.

PubMed: 37736196
DOI: 10.1021/acsmedchemlett.3c00242

実験手法

X-RAY DIFFRACTION (2.378 Å)